Article
Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, KEAP1/STK11 co-mutated metastatic NSCLC.
Frontiers in immunology - 1 Jan 2024
Roussot Nicolas, Thibaudin Marion, Fumet Jean-David, Daumoine Susy, Hampe Léa, Rébé Cédric, Limagne Emeric, Lagrange Aurélie, Herreros Victor, Lecuelle Julie, Mananet Hugo, Ilie Alis, Rageot David, Boidot Romain, Goussot Vincent, Comte Anthony, Jacob Pierre, Beltjens Françoise, Bergeron Anthony, Charon-Barra Céline, Arnould Laurent, Derangère Valentin, Ladoire Sylvain, Truntzer Caroline, Ghiringhelli François
Abstract excerpt
A patient with a PD-L1-negative, TMB-low, KEAP1/STK11 co-mutated metastatic non-small cell lung cancer (NSCLC) experienced a multisite radiological progression at 3 months after initiation of chemoimmunotherapy as first-line treatment for metastatic disease. After the radiological progression, while she was not undergoing treatment, the patient had spontaneous lesions shrinkage and further achieved a prolonged...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.